Image

Efficiency of Spatially Distributed Sequential Stimulation (Sdss) for Functional Electrical Stimulation (FES) of Upper Motor Neuron Syndrome (UMR) Patients

Recruiting
18 - 80 years of age
Both
Phase N/A

Powered by AI

Overview

To determine whether Spatially Distributed Sequential Functional Electrical Stimulation is more effective than Standard Electrical Stimulation During Functional Electrical Stimulation in Upper Motor Neuron Patients

Description

Design: SCED (single case experimental design) prospective, monocentric, comparative interventional study (SDSS versus SES) Population: patients with motor deficit due to upper motor neuron syndrome Setting: Neurologic Rehabilitation Unit Interventions: 3 FES cycling sessions separated by 48h of rest. Each session is comprised of 2 phases separated by 20 minutes of rest. Each phase is comprised of a 3 minutes passive cycling warm-up, followed by 3 minutes of electrically stimulated cycling.

Participants will be evaluated before and during the training.

Eligibility

Inclusion Criteria:

Patients with Upper Motor Neuron syndrome:

  • adult (> 18 years)
  • motor deficit due to an acquired traumatic or neurodegenerative motor deficiency of the central nervous system (MRC<4/5)
  • stable clinical condition, particularly on the cardiovascular level (recent assessment by a cardiologist with stress test)
  • non denervated muscles
  • tolerant to muscle electrical stimulation
  • having given written consent
  • able to cycle 30 minutes with FES-cycling

Exclusion Criteria:

  • major cognitive comprehension disorders that could compromise understanding of the protocol and the smooth running of the study
  • cardiac pacemaker and other contraindications relating to the use of electrostimulation (in particularly "deep vein thrombosis")
  • spasticity of the lower limbs making flexion/extension movement difficult
  • participation in another study
  • pregnancy
  • people with the following legal and administrative states or situations:
  • people placed under judicial protection;
  • persons deprived of their liberty, persons subject to psychiatric care and persons admitted to a health or social establishment for purposes other than that of clinical investigation;
  • unemancipated minors;
  • people who are not affiliated to a social security scheme or beneficiaries of such a scheme

Study details

Upper Motor Neuron Disease

NCT06421753

UGECAM Rhône-Alpes

28 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.